EyeGate Pharmaceuticals has completed a registered direct offering totaling $5 million, according to a press release.
Priced at-the-market under Nasdaq, the 500,000 shares of EyeGate’s common stock were sold at $10 per share, with H.C. Wainwright & Co. acting as the offering’s exclusive placement agent, the release said.
Proceeds from the offering are intended to support research and development efforts, as well as the acquisition or in-license of other products or product candidates.
In addition, the company completed enrollment in a follow-on pilot study that will evaluate its
Uncategorized